Related MeSH Hierarchy (4)
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Genital Diseases, Female » Adnexal Diseases » Ovarian Diseases » Ovarian Cysts » Polycystic Ovary Syndrome
Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Genital Diseases, Female » Adnexal Diseases » Ovarian Diseases » Ovarian Cysts » Polycystic Ovary Syndrome
Diseases [C] » Neoplasms [C04] » Cysts » Ovarian Cysts » Polycystic Ovary Syndrome
Diseases [C] » Endocrine System Diseases [C19] » Gonadal Disorders » Ovarian Diseases » Ovarian Cysts » Polycystic Ovary Syndrome
Description
A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading. MeSH
Hierarchy View
Approved Indicated Drugs (1)
Phase 4 Indicated Drugs (62)
Phase 3 Indicated Drugs (21)
Phase 2 Indicated Drugs (24)
Phase 1 Indicated Drugs (7)
Other Experimental Indicated Drugs (40)
Organization Involved with Phase 4 Indications (87)
AGUNCO Obstetrics and Gynecology Centre
Aristotle University of Thessaloniki
Auckland Medical Research Foundation
Centre Hospitalier Departemental Vendee
Chinese Academy of Medical Sciences
Fasa University of Medical Sciences
Federal University of Health Science of Porto Alegre
Hospital Privado de Cordoba, Argentina
Huazhong University of Science and Technology
Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
Jeanne de Flandre Hospital, Lille
Jean Rostand Intercommoned Hospital
Katholieke Universiteit Leuven
National Institutes of Health (NIH)
Norwegian University of Science and Technology
Our Lady of Lourdes Hospital Waregem
People's Liberation Army of China
Universidad Complutense de Madrid
University of British Columbia
University of California, San Diego
Organization Involved with Phase 3 Indications (60)
Organization Involved with Phase 2 Indications (33)
Beijing Fengtai Hospital of Integrated Traditional and Western Medicine
Beijing First Hospital of integrated Chinese and Western Medicine
Genesis Center for Fertility & Human Pre-Implantation Genetics
Jiangxi University of Traditional Chinese Medicine
Metabolic Center of Louisiana Research Foundation
Misr University for Science and Technology
National Center for Complementary and Integrative Health (NCCIH)
Organization Involved with Phase 1 Indications (15)
Organization Involved with Other Experimental Indications (65)
All India Institute of Medical Sciences
Altamedica Reproductive Medicine
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Dr Patil's Fertility & Endoscopy Clinic, Bangalore
Etlik Zubeyde Hanim Womens' Health and Teaching Hospital
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Heilongjiang University of Traditional Chinese Medicine
Iuliu Hatieganu University of Medicine and Pharmacy
Kar Clinic & Hospital Pvt. Ltd.
National Research Agency, France
National University of Ireland
Shreyas Hospital & Sushrut Assisted Conception Clinic, Kolhapur
The Adelaide and Meath Hospital
University Hospital Quirón Dexeus, Barcelona
University of California, Davis
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.